Analysts Estimate Kenvue (KVUE) to Report a Decline in Earnings: What to Look Out for
Kenvue (KVUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
53 July Dividend Kings: Buy 8, Watch 8 More
"What is a Dividend King? A stock with 50 or more consecutive years of dividend increases."—suredividend.com. The 53 Dividend Kings, screened as of July 8, represented 8 of 11 Morningstar Sectors. Broker-targeted top-ten net-gains ranged 18.24%-30.31% topped-by Kenvue, and Genuine Parts. By yield, Altria tops-all. Top-ten July listings: SWK, FRT, KVUE, FTS, UBSI, BKH, NWN, CDUAF, UVV, MMM, & MO averaged 5.37% in yield.
Kenvue: Portfolio Of Products Can Be Replaced With Generic Brands
Kenvue (KVUE) was created as the result of a spinoff from Johnson & Johnson and encompasses the consumer side of the business. KVUE manages a wide array of products within each segment, but sales volume remains vulnerable to consumer spending. Data shows us that consumers are willing to go with store-branded generics as an alternative to name brands under KVUE's umbrella to save money.
3 Healthcare Stocks to Buy Now: May 2024
It's a great time to be looking at healthcare stocks to buy now. According to research from BlackRock, U.S. healthcare stocks have outperformed the overall stock market by an average of 10% over the past seven recessions.
